SUBJECT TO COMPLETION, DATED SEPTEMBER 15, 2020
PRELIMINARY PROSPECTUS
Healthcare Trust, Inc.
7.375% Series A Cumulative Redeemable Perpetual Preferred Stock
(Liquidation Preference $25.00 Per Share)
This prospectus relates to the offer and sale, from time to time, by the selling holder identified on page 140 of up to $15.0 million of shares of our 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock with a liquidation preference of $25.00 per share and referred to herein as the “Series A Preferred Stock” or the “shares.” B. Riley Principal Capital, LLC, a Delaware limited liability company, also referred to herein as the “selling stockholder” or “B. Riley Principal Capital,” has agreed to purchase from us up to $15.0 million worth of shares of Series A Preferred Stock pursuant to the terms of the Preferred Stock Purchase Agreement we entered into with B. Riley Principal Capital on September 15, 2020, or the “Equity Purchase Agreement.” This arrangement is referred to herein as the “Equity Line.” B. Riley Principal Capital as the selling stockholder hereunder may sell any shares of Series A Preferred Stock offered under this prospectus at fixed prices, prevailing market prices at the time of sale, at varying prices or negotiated prices. For these purposes, B. Riley Principal Capital is an “underwriter” within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), in connection with the resale of the Series A Preferred Stock, and any broker-dealers or agents that are involved in resales may be deemed to be “underwriters” within the meaning of the Securities Act in connection therewith. In this event, any commissions received by the broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. For more information, please see the section of this prospectus titled “Plan of Distribution” beginning on page 141. We will not receive any proceeds from the resale of Series A Preferred Stock by the selling stockholder. We will, however, receive proceeds from the sale of shares directly to B. Riley Principal Capital pursuant to the Equity Line.
Dividends on the Series A Preferred Stock are payable quarterly in arrears on the 15th day of each January, April, July and October of each year (or, if not a business day, the next succeeding business day) to holders of record on the applicable record date. The Series A Preferred Stock ranks senior to our common stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up. The Series A Preferred Stock has no stated maturity and will remain outstanding indefinitely unless redeemed, converted or otherwise repurchased. Except in limited circumstances relating to our qualification as a real estate investment trust for U.S. federal income tax purposes (“REIT”), and as described below, the Series A Preferred Stock is not redeemable prior to December 11, 2024. On and after December 11, 2024, at any time and from time to time, the Series A Preferred Stock is redeemable in whole or in part, at our option, at a cash redemption price of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. In addition, upon the occurrence of a Delisting Event or a Change of Control (each as defined herein), we may, subject to certain conditions, at our option, redeem the Series A Preferred Stock, in whole or in part, after the first date on which the Delisting Event occurred or within 120 days after the first date on which the Change of Control occurred, as applicable, by paying the liquidation preference of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. If we exercise any of our redemption rights, the holders of Series A Preferred Stock will not have the conversion right described below.
Upon the occurrence of a Change of Control during a continuing Delisting Event (each as defined herein), unless we have elected to exercise our redemption right, holders of the Series A Preferred Stock have the right to convert some or all of the Series A Preferred Stock they hold into a number of shares of our common stock, par value $0.01 per share, per share of Series A Preferred Stock, which is equal to the lesser of:
•
the quotient obtained by dividing (1) the sum of the $25.00 liquidation preference per share of Series A Preferred Stock to be converted plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared) on the Series A Preferred Stock to, but not including, the Conversion Date (as defined herein) (unless the Conversion Date is after a dividend record date and prior to the corresponding dividend payment date, in which case no additional amount for the accrued and unpaid dividend will be included in this sum), by (2) the Common Stock Price; and
•
2.8571, the Share Cap, subject to certain adjustments;
subject, in each case, to provisions for the receipt of alternative consideration as described in this prospectus.
Holders of Series A Preferred Stock have no voting rights unless we fail to pay dividends for six or more quarterly periods, whether or not consecutive, or with respect to certain specified events. The Series A Preferred Stock are not subject to any sinking fund. Our capital stock, including the Series A Preferred Stock, is subject to certain restrictions on ownership and transfer that assist us, among other purposes, in maintaining our status as a REIT for U.S. federal income tax purposes. See “Description of Capital Stock — Restrictions on Transfer and Ownership of Stock.”
The Series A Preferred Stock is listed on The Nasdaq Global Market under the symbol “HTIA.” On September 14, 2020, the closing sale price was $21.00 per share.
Investing in the Series A Preferred Stock involves risks, including those that are described in the “Risk Factors” section beginning on page 12 of this prospectus as well as the risk factors contained in the reports or information we file with the Securities and Exchange Commission (the “SEC”), and which are incorporated by reference herein. You should rely only on the information contained in this prospectus or any prospectus supplement or amendment thereto. We have not authorized anyone to provide you with different information. This prospectus may only be used where it is legal to sell these securities. The information in this prospectus is only accurate on the date of this prospectus, regardless of the time of any sale of securities.
The date of this prospectus is , 2020.